NCT03562507终止2 期
ERICA: Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- 1. The Percentage of Patients That Respond to Treatment With the Combination of ESK981 Monotherapy and Nivolumab Therapy (Cohort B).
研究概览
简要总结
The objective of the trial is to determine the clinical efficacy of ESK981 in combination with nivolumab therapy in patients with metastatic renal cell carcinoma (RCC).
详细描述
The study was terminated early due to changes in the RCC treatment landscape which limited the patient population. Due to this early termination no subjects were enrolled into Cohort B.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic diagnosis of renal cell carcinoma (any histology except medullary carcinoma or collecting duct carcinoma is acceptable) with radiologic or histologic evidence of metastatic disease.
- •Prior treatment with up to one (and only one) anti-VEGF or VEGFR inhibitor (small molecule or antibody).
- •Must have measurable disease as per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) criteria.
- •Must be of age ≥ 18 years at time of informed consent.
- •Ability to understand and the willingness to sign a written informed consent.
- •Karnofsky Performance Status ≥
- •(The Karnofsky Performance Status Scale is an assessment tool for functional impairment. It can be used to compare effectiveness of different therapies and to assess the prognosis in individual patients. In most serious illnesses, the lower the Karnofsky score, the worse the likelihood of survival.)
- •Most recent systemic therapy or most recent radiation therapy ≥ 2 weeks of first study drug dose.
- •Recovery to baseline or < Grade 1 CTCAE v.4.03 from toxicities related to any prior treatments, unless AE(s) are clinically non-significant and/or stable on supportive therapy.
- •Women of childbearing potential must have a negative serum or urine pregnancy test within 28 days prior to registration.
- •Adequate organ and marrow function
排除标准
- •Prior treatment for metastatic disease with >1 anti-VEGF/VEGFR inhibitor.
- •Prior treatment with anti-PD/PD-L1/CTLA4/IDO antibody (for Cohort B patients only) or ESK981 (for Cohort A and Cohort B patients).
- •Prior mTOR inhibitors or glutaminase inhibitors are allowed.
- •Untreated brain metastases or spinal cord compression.
- •Uncontrolled hypertension defined as blood pressure >150/90 despite at least 2 anti-hypertensive medication(s) as assessed by 2 blood pressure readings taken at least 1 hour apart during screening.
- •Major surgical procedure or significant traumatic injury within 6 weeks prior to study registration (> 6 weeks prior to registration is permitted as long as they have fully recovered from any such procedure).
- •History of another primary malignancy except for: malignancy treated with curative intent and no known active disease for ≥2 years, adequately treated non-melanoma skin cancer without current evidence of active disease, adequately treated carcinoma in situ without current evidence of active disease, Gleason ≤6 prostate cancer.
- •Angina, myocardial infarction symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, percutaneous angioplasty or coronary arterial bypass surgery within the past 3 months.
- •History of gastrointestinal perforation or fistula in the past 6 months, or while previously on antiangiogenic therapy, unless underlying risk has been resolved (e.g. through surgical resection or repair).
- •The patient has known hypersensitivity to gelatin or lactose monohydrate.
- •The patient has received any investigational drug within 28 days prior to registration or 5 half-lives of the investigational drug, whichever is shorter.
- •History of bleeding disorders (e.g. pulmonary hemorrhage, significant hemoptysis, menometrorrhagia not responding to hormonal treatment) ≤ 6 weeks before Cycle 1 Day
- •The patient is on a chronic daily medication known to be a severe or moderate inhibitor or inducer by Micromedex of CYP1A2, CYP2C8, or CYP3A4 at registration.
- •Systemic corticosteroids greater than the equivalent of 10 mg of prednisone or equivalent alternative steroid (except physiologic dose for adrenal replacement therapy) or other immunosuppressive agents (such as cyclosporine or methotrexate) and any other medications that could potentially impact the efficacy or safety of the study as judged by the treating investigator are NOT permitted from time of registration to subjects completing protocol therapy unless clinically indicated to manage adverse events or life threatening or serious conditions as determined by the treating investigator.
- •Have any condition that, in the opinion of the investigator, would compromise the ability of the subject to meet or perform study requirements.
研究组 & 干预措施
ESK981 and Nivolumab
Experimental
ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
Nivolumab: 480 mg/dose IV, Day 1 of each 28-day cycle
干预措施: Nivolumab (Drug)
ESK981 Monotherapy
Experimental
ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
干预措施: ESK981 (Drug)
ESK981 and Nivolumab
Experimental
ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
Nivolumab: 480 mg/dose IV, Day 1 of each 28-day cycle
干预措施: ESK981 (Drug)
结局指标
主要结局
1. The Percentage of Patients That Respond to Treatment With the Combination of ESK981 Monotherapy and Nivolumab Therapy (Cohort B).
时间窗: Up to 24 months after last dose of study treatment
The percentage of patients in Cohort B that achieve a complete response (CR) or partial response (PR). Response will be assessed by combined Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Immune-related (ir)RECIST.
次要结局
- Duration of Response(Up to 24 months after last dose of study treatment)
- The Percentage of Patients That Respond to Treatment With ESK981 Monotherapy (Cohort A).(Up to 24 months after last dose of study treatment, 5 month treatment duration on average, no CR or PR responses were recorded.)
- Duration of Therapy(Up to approximately 24 months after treatment start)
- Median Overall Survival Time(Up to 24 months after last dose of study treatment)
- Progression Free Survival Time(Up to 24 months after last dose of study treatment)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerCastration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaProstate Carcinoma Metastatic in the BoneStage IVB Prostate Cancer AJCC v8NCT04159896Barbara Ann Karmanos Cancer Institute10
已完成
2 期
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate CancerCastration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaPSA ProgressionStage IV Prostate Adenocarcinoma AJCC v7NCT03456804Barbara Ann Karmanos Cancer Institute13
进行中（未招募）
2 期
Multicenter Trial of ESK981 in Patients With Select Solid TumorsPancreatic AdenocarcinomaPancreatic Neuroendocrine CarcinomaGastrointestinal Neuroendocrine TumorGastrointestinal Neuroendocrine CarcinomaNeuroendocrine Prostate CarcinomaPancreatic Neuroendocrine TumorAdenosquamous CarcinomaNCT05988918University of Michigan Rogel Cancer Center17
已完成
1 期
A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR MutationLung CancerNon-Small Cell Lung CancerNCT01859026H. Lee Moffitt Cancer Center and Research Institute43
已完成
2 期
A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)Diabetes Mellitus, Type 2NCT00631488Merck Sharp & Dohme LLC146